Trialling a double-dose of influenza vaccine to examine the efficacy of the influenza vaccination in patients with chronic obstructive pulmonary disease (COPD)

Phase 4

Completed

• Conditions: Chronic Obstructive Pulmonary Disease; Influenza viral disease; Respiratory - Chronic obstructive pulmonary disease; Infection - Other infectious diseases

• Registration Number: ACTRN12620000954921
• Lead Sponsor: Princess Alexandra Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2018-08-29
• Study Start: 2020-09-25
• Last Update Posted: 5 October 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 41

Inclusion Criteria

Mild to very Severe COPD with a post bronchiodilater FEV1 less than 80%.
Predicted FEV1/FVC ratio less than 0.8.
COPD patients will be stable with no COPD exacerbations or respiratory infections within the 4 weeks prior to participating in the study.

Exclusion Criteria

Invasive malignancy within the last 2 years.
Renal impairment (eGFR less than 40 ml/min).
Acute febrile illness with fever greater than 38.5 degrees Celsius.
Hypersensitivity to egg protein.
Use of oral Prednisolone or equivalent. greater than or equal to 10 mg per day.
Use of other systemic immunosuppressive therapy.
Anaphylaxis following a previous dose of influenza vaccine.
Anaphylaxis following a vaccine component (including eggs).
History of Guilliane Barre within 6 weeks of a previous influenza vaccination
Non-stable cardiac disease, non-stable diabetes mellitus, and some skin cancers as assessed by the principal investigator,

Study & Design

• Study Type: Interventional
• Study Design: Not specified